Search alternatives:
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
point decrease » point increase (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
-
38901
-
38902
-
38903
Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively...
Published 2019“…We found that co-treatment of SLCP and berberine produced more glioblastoma cell death, more DNA fragmentation, and significantly decreased ATP levels and reduced mitochondrial membrane potential than did single treatments in both glioblastoma cells lines. …”
-
38904
-
38905
-
38906
-
38907
WTA stimulates in vitro T-cell activation by a MHC-II dependent mechanism.
Published 2010“…An antibody to HLA-DR (5 µg/ml) inhibited T-cell proliferation induced by zwitterionic wt WTA (<i>p</i><0.0001) but not negatively charged <i>dltA</i> WTA. …”
-
38908
-
38909
-
38910
-
38911
-
38912
Image_8_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38913
Image_7_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38914
Image_10_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38915
Image_15_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38916
Image_13_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38917
Image_11_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38918
Image_14_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38919
Image_6_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
-
38920
Image_1_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif
Published 2023“…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”